Bleeding-Related Interactions Between DOACs and Cardiovascular Drugs: Insights from FDA adverse event reporting system
Listen to this summary
This study aimed to identify bleeding-related drug interactions between direct oral anticoagulants (DOACs) and cardiovascular medications in patients undergoing polypharmacy, utilizing data from the FDA Adverse Event Reporting System. The authors found 15 significant DOAC-drug combinations associated with increased bleeding risk, particularly involving diuretics and specific cardiovascular drugs, highlighting the importance of considering polypharmacy in DOAC selection and monitoring for bleeding events.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from The American journal of medicine
View all →May 9, 2026 · The American journal of medicine
From obesity to cardiovascular disease: pathological basis and clinical implications
May 8, 2026 · The American journal of medicine
Management of salt-sensitive hypertension in clinical settings: how should we approach it?
May 8, 2026 · The American journal of medicine
Circulating Apolipoprotein E concentration and incident cardiovascular diseases: evidence from an electronic health record-based cohort
May 7, 2026 · The American journal of medicine
A retrospective study of the usefulness of pleural effusion and blood indicators and ratios in detecting benign and malignant pleural effusion
May 7, 2026 · The American journal of medicine
Addressing Racism as a Clinical Competence: Robert Wilson, Jr. (1867-1946)
May 5, 2026 · The American journal of medicine
On a Platform in Chhattisgarh
More in Internal Medicine
View all →May 10, 2026 · JAMA
Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis
May 10, 2026 · European heart journal
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trial
May 10, 2026 · Lancet (London, England)
Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication
May 10, 2026 · JAMA
Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial
May 10, 2026 · European heart journal
Renin-angiotensin-aldosterone system inhibition and haemocompatibility-related adverse events in patients with durable left ventricular assist device: the MOMENTUM-3 trial
May 10, 2026 · Lancet (London, England)
Impact of introducing RTS,S/AS01<sub>E</sub> malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
